851 related articles for article (PubMed ID: 33995389)
21. Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.
Zhou H; Yang M; Cui L; Jiang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107072. PubMed ID: 33059198
[TBL] [Abstract][Full Text] [Related]
22. Toxicities following CAR-T therapy for hematological malignancies.
Hernani R; Benzaquén A; Solano C
Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.
Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y
J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
25. Recognizing, defining, and managing CAR-T hematologic toxicities.
Rejeski K; Subklewe M; Locke FL
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):198-208. PubMed ID: 38066881
[TBL] [Abstract][Full Text] [Related]
26. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T-cell therapy: An emergency medicine focused review.
Long B; Yoo MJ; Brady WJ; Holian A; Sudhir A; Gottlieb M
Am J Emerg Med; 2021 Dec; 50():369-375. PubMed ID: 34461398
[TBL] [Abstract][Full Text] [Related]
28. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.
Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J
J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789
[TBL] [Abstract][Full Text] [Related]
29. Critical care management of chimeric antigen receptor T-cell therapy recipients.
Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
[TBL] [Abstract][Full Text] [Related]
30. [Practical aspects of the application of CAR T cells and management of their toxicities].
Bücklein V; Blumenberg V; Subklewe M
Dtsch Med Wochenschr; 2021 Sep; 146(17):1129-1137. PubMed ID: 34448189
[TBL] [Abstract][Full Text] [Related]
31. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
32. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
33. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy
Chen Y; Li R; Shang S; Yang X; Li L; Wang W; Wang Y
Front Immunol; 2021; 12():623610. PubMed ID: 34093519
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
36. Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers.
Perez A; Al Sagheer T; Nahas GR; Linhares YPL
Front Immunol; 2024; 15():1412002. PubMed ID: 38779668
[TBL] [Abstract][Full Text] [Related]
37. Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy.
Johnson PC; Neckermann I; Sadrzadeh H; Newcomb R; El-Jawahri AR; Frigault MJ
Transplant Cell Ther; 2024 May; 30(5):490-499. PubMed ID: 38412928
[TBL] [Abstract][Full Text] [Related]
38. Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?
Murthy HS; Yassine F; Iqbal M; Alotaibi S; Moustafa MA; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):100-111. PubMed ID: 36395496
[TBL] [Abstract][Full Text] [Related]
39. Adoptive therapy with CAR redirected T cells for hematological malignancies.
Li S; Yang Z; Shen J; Shan J; Qian C
Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
[TBL] [Abstract][Full Text] [Related]
40. Neurological Complications of CAR T Cell Therapy.
Landry K; Thomas AA
Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]